Open Site Navigation

Porphyromonas gingivalis: where do we stand in our battle against this oral pathogen?

Kaitlind C. Howard, Octavio A. Gonzalez and Sylvie Garneau-Tsodikova (2021)


Periodontal diseases, such as gingivitis and periodontitis, are inflammatory diseases triggered by pathogenic bacteria that lead to damage of the soft tissue and bone supporting the teeth. Amongst the identified oral periodontopathogenic bacteria, Porphyromonas gingivalis is able to enhance oral dysbiosis, which is an

imbalance in the beneficial commensal and periodontal pathogenic bacteria that induces chronic inflammation. Given the critical role of oral pathogenic bacteria like P. gingivalis in the pathogenesis of periodontitis, local and/or systemic antibacterial therapy has been suggested to treat this disease, especially in its severe or refractory forms. Nevertheless, the majority of the antibacterial agents currently used for the treatment of periodontal diseases are broad-spectrum, which harms beneficial bacterial species that are critical in health, inhibit the growth of pathogenic bacteria, contribute in protecting the periodontal tissues to damage and aid in its healing. Thus, the development of more effective and specific antibacterial agents is needed to control oral pathogens in a polymicrobial environment.


Porphyromonas gingivalis - where do we stand in our battle against this oral pathogen_
.pdf
Download PDF • 11.38MB

©2022 by Direct Diagnostics LLC. Direct Diagnostics is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meets the requirements to perform high complexity tests. CLIA Registration 45D2190910. 

Direct Diagnostics is certified under the College of American Pathologists (CAP), CAP Accreditation #9088531

Website by Redwood Designs.

  • Instagram
  • LinkedIn | Direct Dx
  • Facebook
  • YouTube